Turbo Cancer Treatment race is on: Johnson & Johnson just completed $2 billion cancer drug buy of Ambrx on March 7, 2024 - Merck, Novartis, Sanofi, Eli Lilly, AbbVie, Pfizer, BMS - they all want in!

Articles reviewed:

• Mar.11, 2024 - Pfizer bets on cancer drugs to recover from rapid decline of COVID business

• Mar.11, 2024 - Merck Completes Acquisition of Harpoon Therapeutics

• Mar.7, 2024 - Johnson & Johnson Completes Acquisition of Ambrx ($2.0 billion)

• Feb.12, 2024 - AbbVie Completes $10.1 billion Acquisition of ImmunoGen

• Feb.5, 2024 - Novartis in the lead to acquire cancer drug developer MorphoSys-sources

• Dec.26, 2023 - Bristol Myers Squibb announces intent to buy RayzeBio for $4.1 billion (104% premium)

• Nov.22, 2023 - Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

• Oct.8, 2023 - Bristol Myers Squibb announces purchase of Mirati Therapeutics for $5.8 billion

• Oct.3, 2023 - Eli Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies